

Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3 **1 FTIR Imaging of Structural Changes in Visceral and Subcutaneous**

4
5
6 **2 Adiposity and Brown to White Adipocyte Transdifferentiation**

7
8
9
10
11
12 **4 Fatma KUCUK BALOGLU¹, Sebnem GARIP², Sebastian HEISE³, Gudrun BROCKMANN³,**
13
14 **5 Feride SEVERCAN^{1*}**

15
16
17
18
19 **7 ¹Department of Biological Sciences, Middle East Technical University, Ankara, Turkey**

20
21 **8 ²Department of Medical Biochemistry, Faculty of Medicine, Istanbul Kemerburgaz**

22
23
24 **9 University, Istanbul, Turkey**

25
26 **10 ³Department of Breeding Biology and Molecular Genetics, Humboldt Universitat zu Berlin,**
27
28 **11 Berlin, Germany**

29
30
31
32
33 **13 *Corresponding Author: Feride Severcan**

34
35 **14 Department of Biological Sciences**

36
37 **15 Middle East Technical University**

38
39 **16 06531, Ankara, TURKEY**

40
41 **17 Tel: +90-312-210 51 66**

42
43 **18 Fax: +90-312-210 79 76**

44
45 **19 E-mail: feride@metu.edu.tr**

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 27 **Abstract**
4

5 28 Obesity is a heterogeneous disorder which increases risks for multiple metabolic diseases,
6
7
8 29 such as type 2 diabetes. The current study aims to characterize and compare visceral and
9
10 30 subcutaneous adipose tissues in terms of macromolecular content and investigate
11
12 31 transdifferentiation between white and brown adipocytes. Regarding this aim, Fourier
13
14 32 transform infrared (FTIR) microspectroscopy and uncoupling protein 1 (UCP1)
15
16 33 immunohistological staining was used to investigate gonadal (visceral) and inguinal
17
18 34 (subcutaneous) adipose tissues of male Berlin fat mice inbred (BFMI) lines, which are
19
20 35 spontaneously obese. The results indicated a remarkable increase in the lipid/ protein ratio,
21
22 36 accompanied with a decrease of UCP1 protein content which might be due to the
23
24 37 transdifferentiation of brown adipocytes to white adipocytes in obese groups. It has been
25
26 38 widely reported that brown adipose tissue has a strong effect on fatty acid and glucose
27
28 39 homeostasis and it could provide opportunity for therapy of obesity. When the amount of
29
30 40 brown adipose tissue was decreased, lower unsaturation/saturation ratio, qualitatively longer
31
32 41 hydrocarbon acyl chain length of lipids and higher amount of triglycerides were obtained in
33
34 42 both adipose tissues of mice lines. The results also revealed that subcutaneous adipose tissue
35
36 43 was more prone to obesity-induced structural changes, than visceral adipose tissue, which
37
38 44 could be originated from possessing a lower amount of brown adipose tissue. The current
39
40 45 study clearly revealed the power of FTIR microspectroscopy in the precise determination of
41
42 46 obesity-induced structural and functional changes in inguinal and gonadal adipose tissue of
43
44 47 mice lines.
45
46
47
48
49
50
51
52
53
54

55 49 **Keywords:** Obesity, visceral adipose tissue, subcutaneous adipose tissue, white adipose
56
57 50 tissue, brown adipose tissue, UCP1 protein, FTIR imaging, transdifferentiation.
58
59
60

1. Introduction

Obesity results from a prolonged imbalance between the level of energy intake and expenditure leading to excessive weight gain. It is also referred to as an epidemic disease caused by the modern life style which affects increasing number of people of all social conditions throughout the world.¹ Obesity is becoming one of the major public health problems. The World Health Organization reported that more than 1.4 billion adults were overweight and over 200 million men and nearly 300 million women of them were obese.² Epidemiologic studies estimate that by the year 2030, 2.16 billion people worldwide will be overweight and 1.12 billion will be obese.³ Obesity results in accumulation of triglycerides in adipose tissues and the enlargement of adipocytes.⁴ An excessive accumulation of lipid droplets in cytoplasm may lead to cellular dysfunction or cell death, a phenomenon known as lipotoxicity.^{5,6}

Adipose tissue is an essential, complex and metabolically active endocrine organ which is distributed in a variety of locations in the body different than the other organs.^{7,8} Adipose tissue depots are composed of two cytotypes. These cytotypes are white adipose tissue and brown adipose tissue. White adipocytes are spherical cells whose variable size mainly depends on the size of the single lipid droplet stored in them. This lipid droplet consists of triglycerides and accounts for more than 90% of the cell volume. Brown adipocytes also contain triglycerides as multiple small vacuoles; they are typically polygonal with a variable diameter. The most characteristic organelles of brown adipocytes are the mitochondria. Because of its greater oxygen demand, brown fat also contains more capillaries than white fat. Nerve supply is also denser in brown adipose tissue than in white adipose tissue. The brown color of brown adipocytes is attributable to its high mitochondrial density and high vascularization.^{9,10} The amount of these two types of adipose tissues in the body shows variety according to strain, gender, age, nutritional environmental factors. Brown adipocytes

1
2
3 77 have a completely different role than white adipocytes since they are responsible for
4
5 78 thermogenesis. They transfer the energy achieved from nutrition to thermal energy.^{11,12}
6
7
8 79 Uncoupling protein 1 (UCP1), which is mostly expressed in brown adipose tissue, is
9
10 80 responsible for the transformation of the energy that is not used in oxidative metabolism into
11
12 81 heat.¹³ Noradrenaline is responsible for the activation of beta-3-adrenoceptors which induces
13
14 82 brown adipocytes to produce heat. When brown adipocytes are not stimulated adrenergically,
15
16 83 they lose most of their brown characteristics and transdifferentiate into white adipocytes.^{14,15}
17
18 84 This reversible morphological transformation occurs with leptin gene activation and UCP-1
19
20 85 gene inhibition.¹⁶ In rodents, brown adipose tissue phenotype in adipose tissues is very
21
22 86 important for the prevention of many metabolic diseases such as obesity and diabetes.¹⁴
23
24
25 87 FTIR spectroscopy was previously applied to obesity research for determination of fatty acid
26
27 88 content in human abdominal fat,¹⁷ and recently to high fat diet induced obesity in BXD
28
29 89 recombinant inbred mice lines to identify specific gene loci responsible for the variations in
30
31 90 the molecular tissue compositions.¹⁸ In the current study, FTIR microspectroscopy was
32
33 91 applied to identify spontaneous obesity-induced molecular changes in adipose tissues of
34
35 92 inbred obese mice lines. Fourier transform infrared (FTIR) microspectroscopy enables the
36
37 93 visualization of the distribution of molecules in a tissue.¹⁹⁻²² Due to the sensitivity of FTIR
38
39 94 microspectroscopy and the information on spatial heterogeneity possessed in the images, IR
40
41 95 spectral images give information on the histological structure of the tissue without the
42
43 96 application of staining procedures.²³ In this technique, every pixel includes a spectrum which
44
45 97 is recorded sequentially, and the pixels are collected together to form a larger image. The
46
47 98 recorded information by IR microscopy is represented by false-color images that simulates the
48
49 99 images as histological-stained samples.²⁴
50
51
52
53
54
55
56
57
58 100 In this study, FTIR microspectroscopic imaging was performed to determine the distribution
59
60 101 of molecules, especially lipids, in two different adipose tissues; inguinal adipose tissue as a

1
2
3 102 subcutaneous adipose tissue, gonadal adipose tissue as a visceral adipose tissue, and also to
4
5 103 figure out the obesity-induced structural variations in the lipids. For this purpose, inguinal and
6
7
8 104 gonadal adipose tissues of control (DBA/J2) and spontaneous obese (BFMI) lines were used.
9
10 105 In addition, UCP1 immunohistological staining was performed to differentiate brown adipose
11
12 106 tissue and white adipose tissue; so transdifferentiation between brown and white adipocytes of
13
14
15 107 these tissues were investigated.
16
17
18 108

19 20 109 **2. Experimental**

21 22 110 **2.1 Animals**

23
24 111 All experimental protocols regarding treatment of animals were approved by the German
25
26 112 Animal Welfare Authorities (approval no. G0171/10). Founder animals of the Berlin Fat Mice
27
28 113 lines were originally purchased from several pet shops in Berlin, Germany. These mice were
29
30 114 selected during 58 generations, according to low protein content and then to low body weight
31
32 115 and high fat content. Then, BFMI line's inbred derivatives were generated and these lines were
33
34 116 created by brother and sister mated randomly chosen sib-pairs of the selected lines.²⁵
35
36 117 In this study, 10 weeks old males of BFMI852, BFMI856, BFMI860 and BFMI861 inbred
37
38 118 lines which were separated in terms of phenotypic characteristics after six generations of
39
40 119 inbreeding, were used. Due to the selection history of the lines, different genetic
41
42 120 constellations have been fixed in the process of inbreeding leading to major differences in the
43
44 121 phenotype. There are significant differences between BFMI lines in terms of body fat mass,
45
46 122 body fat percentage, weights of dissected fat pads, inner organs and glucose concentrations.²⁵
47
48 123 BFMI lines 856, 861 and 860 are the most obese lines, whereas only 860 and 861 show
49
50 124 features of the metabolic syndrome and reduced insulin sensitivity. It has been reported that
51
52 125 BFMI860 line has higher serum triglyceride levels in both standard breeding diet and high fat
53
54 126 diet.²⁶ As controls male DBA/J2 mice line was used, which is a commercially available inbred
55
56
57
58
59
60

1
2
3 127 line that is often used as a standard mice showing a wildtype-like phenotype.^{27,28} In the study,
4
5 128 each group contained 6 mice.

6
7
8 129 The mice were maintained under conventional conditions and controlled lighting with a
9
10 130 12:12h light/dark cycle at a temperature of 22±2°C and a relative humidity of 65%. They
11
12 131 were reared in groups of two to three mice in macrolon cages with a 350 cm² floor space (E.
13
14 132 Becker & Co (Ebeco) GmbH, Castrop-Rauxel, Germany) and with dust-free bedding type
15
16 133 S80/150 (Rettenmeier Holding AG, Wilburgstetten, Germany). All mice had *ad libitum*
17
18 134 access to food and water. After weaning at the age of 3 weeks, animals were fed with a rodent
19
20 135 standard breeding diet (SBD). The SBD (V1534-000, ssniff R/M-H, Ssniff Spezialdiäten
21
22 136 GmbH, Soest/Germany) contains 12.8 MJ/kg of metabolisable energy the biggest amount of
23
24 137 which originates from carbohydrates with 58% (33% from proteins and 9% from fat). The fat
25
26 138 content of SBD was derived from soy oil.²⁶
27
28
29
30
31
32
33

34 140 **2.2 Sample preparation**

35
36 141 After 10 weeks, mice were killed by decapitation, inguinal and gonadal adipose tissues of the
37
38 142 mice were dissected and washed with PBS buffer to get rid of the excess blood surrounding
39
40 143 the tissue. They were snap-frozen in liquid nitrogen and stored at -80°C until sectioning.
41
42 144 Three sections were prepared for each sample. For sectioning, the adipose tissue samples were
43
44 145 embedded in Cryomatrix Frozen Embedding Medium (Thermo Scientific, USA). 7 µm thick
45
46 146 adjacent tissue sections were obtained using a cryotome (Shandon, USA) at -25°C both for
47
48 147 FTIR microspectroscopy and immunohistological studies. The tissue sections for FTIR study
49
50 148 were directly transferred onto IR transparent barium fluoride windows (Spectral Systems, NY,
51
52 149 USA). These IR sections were kept in a desiccator with a vacuum pump at cold room for
53
54 150 overnight to remove the moisture from the sections.
55
56
57
58
59
60

151

152 **2.3 Immunohistological staining**

153 The Inguinal and gonadal adipose tissues of BFMI lines and control DBA/J2 line have been
154 used for UCP1 immunohistological staining in order to differentiate brown and white adipose
155 tissues for the monitoring of transdifferentiation. For staining “EXPOSE rabbit specific AP
156 (red) detection IHC Kit” (Abcam, USA) and Biotin goat anti rabbit antibody (Vector Lab.
157 Inc., USA) were used. Immunohistological staining was applied as described in the kit
158 procedure. After drying for overnight in desiccator, slides were treated with acetone at -20°C
159 and waited for 10 minutes at -20°C and then washed 3 times in buffer (PBS). Then, we
160 applied Protein Block and incubated the slides for 10 minutes at room temperature to block
161 nonspecific background staining and wash 3 times in buffer again. In next step, we applied
162 primary antibody (Biotin goat anti rabbit antibody (Vector Lab. Inc., USA)) and incubated the
163 slides according to manufacturer's protocol and washed 3 times in buffer. After that, AP
164 conjugate was applied and the slides were incubated for 30 minutes at room temperature and
165 rinsed 4 times in buffer. The 200 µl of enhancer was applied to the slides and the slides were
166 incubated for 4 minutes at room temperature. We mixed equal volume of Naphthol Phosphate
167 and Fast Red just before using, and then applied 200 µl of this mixture onto the slides with
168 Enhancer. The recommended incubation time was 8 minutes at room temperature. Then, the
169 slides were rinsed 4 times in buffer followed by Hematoxylin staining as a counter-staining.
170 For counter-staining, Hematoxylin was added to cover the slides which were then incubated
171 for 1 minute and they were 7-8 times in tap water. Stained slides were made permanent by
172 Eukitt® quick-hardening mounting medium (Sigma-Aldrich, USA) and they were quantified
173 by observing with a light microscope under 40X magnification.

174

175 **2.4 FTIR Microspectroscopic Data Collection and Analysis**

1
2
3 176 FTIR images were acquired using a Perkin Elmer Spectrum Spotlight 400 Imaging System
4
5 177 (Perkin Elmer Instruments, Boston, MA, USA), including an IR microscope. Images were
6
7
8 178 collected in the transmission mode at a spectral resolution of 8 cm^{-1} in the wavenumber region
9
10 179 between 4000 and 750 cm^{-1} with a $6.25 \times 6.25\text{ }\mu\text{m}$ IR detector pixel size and four scan number
11
12 180 per pixel. Although, adipose tissue is a highly homogenous tissue, we randomly chose three
13
14 181 different areas in each tissue section to collect IR maps. FTIR microscope collects these IR
15
16 182 images by scanning the chosen areas pixel by pixel (pixel size: $6.25 \times 6.25\text{ }\mu\text{m}$) and getting an
17
18 183 IR spectrum from each pixel. The size of the spot or pixel was determined by the size of the
19
20 184 microscope aperture which might be defined as micrometers. Since the size of the collected
21
22 185 IR maps is $700 \times 700\text{ }\mu\text{m}$, totally 12544 spectra were recorded from each chosen area of each
23
24 186 section. Before calculating the spectral parameters, first the average of 12544 spectra was
25
26 187 taken from each area. The average spectra of each area were found to be almost identical.
27
28 188 Then the average spectrum of these three average spectra belong to the chosen areas was used
29
30 189 for each section for further analysis. Thus, the spectral alterations between animal groups
31
32 190 reflect cellular alterations rather than experimental uncertainties. The spectra of empty IR
33
34 191 window were collected as background and subtracted automatically from tissue spectra by the
35
36 192 use of Spotlight Autoimage software (Perkin Elmer Instruments, Boston, MA, USA).
37
38
39
40
41
42
43

44 193 In FTIR microspectroscopic studies of tissues, the main parameter which can affect the results
45
46 194 of cellular alterations is sample thickness. In the analysis of FTIR images, band area ratios
47
48 195 were used in order to avoid the errors that might occur due to possible differences in section
49
50 196 thickness which may **cause** concentration-dependent alterations in the spectral absorbance
51
52 197 values.²⁹⁻³¹ Spectral images were analyzed using ISYS software (Spectral Dimensions, Olney,
53
54 198 MD, USA).
55
56
57
58
59
60

200 **2.5 Statistics**

201 The results were calculated as ‘mean \pm standard error of mean (SE)’. The differences in
202 variance were analyzed statistically using one-way ANOVA test. Tukey’s test was used as a
203 post-hoc test. p values less than or equal to 0.05 were considered as statistically significant
204 (such as $*p \leq 0.05$; $**p \leq 0.01$; $***p \leq 0.001$).

206 **3. Results**

207 Biological samples contain different molecules such as proteins, lipids, nucleic acids and
208 carbohydrates. Hence, all these individual biochemical components have their specific
209 vibrational fingerprints.³²⁻³⁴ By using this property, FTIR microspectroscopic imaging enables
210 to obtain visible images of the investigated tissue, where each pixel is composed of a
211 spectrum originating from vibrational fingerprints. The representative FTIR spectra acquired
212 from control (DBA/J2) and obese (BFMI861) groups of inguinal adipose tissue in the 4000–
213 750 cm^{-1} region are shown in Figure 1. The detailed spectral band assignments of mouse
214 adipose tissue are shown in Table 1.^{18,35,36}

215 In order to determine obesity-induced alterations in the concentration and composition of
216 biomolecules, the area ratios of several functional groups that belong to lipids and proteins
217 were calculated. The wavenumber limits with baseline points used for the band area ratio
218 calculations for each vibrational region, were given in Table 1S as a supporting material. The
219 lipid to protein ratio is an important parameter in molecular asymmetry.³⁷ This ratio was
220 obtained by taking the ratio of the integrated areas of C-H stretching region to the area of the
221 amide I band. The C-H stretching region which contains significant vibrations of the fatty acyl
222 chains of membrane lipids is a sensitive marker for the lipid content.³⁸⁻⁴⁰ Amide I band gives
223 information about total protein concentration and conformation.^{21,41}

1
2
3 224 In order to obtain qualitative information on lipid structure of adipose tissues, carbonyl/lipid
4
5 225 and unsaturated/saturated lipid ratio were calculated. Carbonyl/lipid ratio was calculated by
6
7
8 226 taking the ratio of the area of carbonyl band to that of C-H stretching region.
9
10 227 Unsaturated/saturated ratio was calculated by taking the ratio of the area of the olefinic band
11
12 228 (unsaturated lipid) to that of CH₂ antisymmetric band (saturated lipid). Qualitative lipid acyl
13
14
15 229 chain length changes were monitored by calculating the ratio of areas of the CH₂
16
17 230 antisymmetric band to that of the CH₃ antisymmetric band. Furthermore, lipid and protein
18
19 231 amounts were obtained from CH₂ symmetric/CH₂ antisymmetric and the amide I/ amide I +
20
21 232 amide II ratios, respectively. The comparison of these ratios in terms of bar graphs for the
22
23 233 control (DBA/J2) and 4 different obese (BFMI) male mice lines are shown in figure 2. As
24
25 234 seen from these graphs, the lipid/protein ratio, carbonyl/lipid ratio, lipid amount (CH₂
26
27 235 symmetric/CH₂ antisymmetric) and qualitative lipid acyl chain length changes (CH₂/CH₃
28
29 236 antisymmetric) increased; whereas unsaturated/saturated lipid ratio (olefinic/lipid) and protein
30
31 237 amount (amide I/ amide I + amide II) decreased for obese male mice lines when they were
32
33
34 238 compared with the control (DBA/J2) line.
35
36
37 239 The significant increase in the lipid/protein ratio in the obese groups compared to the control,
38
39 240 might be due to the dramatic increase in the lipid content as seen from CH₂ symmetric/CH₂
40
41 241 antisymmetric ratio and/or from the significant decrease in protein content that we observed in
42
43 242 obese lines.⁴⁰ The increase in the lipid/protein ratio was more remarkable in inguinal adipose
44
45 243 tissue rather than gonadal adipose tissue. This might be due to that inguinal adipose tissue is
46
47 244 prone to deposit lipids rather than gonadal tissue because inguinal tissue is a subcutaneous
48
49 245 adipose tissue, whereas gonadal tissue is a visceral adipose tissue.⁴² The increase of
50
51 246 lipid/protein ratio in obese groups may also be arisen from a lower protein content. The
52
53 247 changes in amide I area/intensity values give information about total protein amount.³⁴ We
54
55 248 obtained a significant decrease in the band area value of the amide I of adipose tissues of
56
57
58
59
60

1
2
3 249 obese groups implying a decrease of protein content in harmony with literature values (Table
4
5 250 2). Decrease in protein content was also supported by the significant decrease of amide I/
6
7
8 251 amide I + amide II ratio (Figure 2). To obtain more information about changes in protein
9
10 252 composition and structure, we calculated the band area ratio of amide I/ amide II (Figure 2).
11
12 253 This ratio decreased in obese lines compared to the control group. Since amide I and amide II
13
14
15 254 profiles depend on the protein structural composition, this decrease suggests that there are
16
17 255 some alterations in the structures of proteins.⁴³⁻⁴⁵ In addition, slight but significant shifting in
18
19 256 the wavenumber of amide I band to higher values was observed in the all obese groups in
20
21
22 257 comparison to the control group (Table 2) which indicates alterations in protein
23
24 258 conformation.⁴⁶⁻⁴⁸ The changes in the spectral parameters related to protein such as; the
25
26
27 259 decrease in the area of amide I band and amide I/amide II band area ratio, and the shifting of
28
29 260 the amide I band to higher wavenumber values, could be interpreted as a result of the
30
31 261 alteration of protein expression which may cause obesity-induced changes in protein structure
32
33 262 and conformation in adipose tissues.

34
35
36 263 The olefinic/lipid ratio can be used as an index of double bonds in the lipid structure
37
38 264 indicating the relative amount of unsaturated lipids.^{21,38} The significant decrease in
39
40
41 265 olefinic/lipid ratio was observed in all obese mice lines compared to the control group,
42
43 266 indicating that unsaturated lipid content decreased in obese mice lines. This ratio was also
44
45
46 267 lower in inguinal adipose tissue rather than in gonadal adipose tissue of all groups.

47
48 268 The carbonyl/lipid ratio gives information about carbonyl ester concentration in lipids of the
49
50 269 system.^{21,49,50} This ratio was slightly higher in BFMI852 and BFMI856 lines but significantly
51
52
53 270 higher in BFMI 860 and BFMI861 lines.

54
55 271 The CH₂ antisymmetric stretching/CH₃ antisymmetric stretching ratio was used to determine
56
57 272 the qualitative changes in hydrocarbon acyl chain length of lipids, where higher ratios indicate
58
59
60 273 the presence of longer chained lipids.^{34,39,51-53} We obtained an increase in this ratio in all obese

1
2
3 274 BFMI lines but they were only significant for BFMI860 and BFMI861 lines. The ratio was
4
5 275 also more significant in inguinal adipose tissue than gonadal adipose tissue in numerous of
6
7
8 276 lines as seen from figure 2. In order to get information about qualitative lipid acyl chain
9
10 277 lengths changes, the ratio of the area of CH₂ antisymmetric stretching band to lipid (C-H
11
12 278 region) was also calculated. The increased ratio values obtained from this ratio also supported
13
14
15 279 relative variations towards to longer acyl chain lengths of lipids in obese mice groups
16
17 280 compared to the control.^{21,54}

18
19
20 281 The representative spectral maps of lipid/protein, olefinic/protein and CH₂/CH₃ antisymmetric
21
22 282 ratios of inguinal adipose tissue of control (DBA/J2) and obese (BFMI861) male mice line
23
24 283 were shown in Figure 3 for both tissue types. Since the obesity-induced changes were seen
25
26
27 284 more dramatically for inguinal adipose tissue of BFMI861 line as seen from Figure 2, the
28
29 285 comparison of FTIR images of this line with the control was presented in Figure 3. The
30
31 286 spectral maps are represented as color-coded images which are composed of a spectrum in
32
33
34 287 each pixel and they were colored according to the calculated ratio values, where red color
35
36 288 corresponds to the highest ratio and blue color corresponds to the lowest ratio as shown on the
37
38
39 289 color bars in the figure. This figure clearly shows the increase in the lipid to protein ratio and
40
41 290 CH₂/CH₃ antisymmetric ratio, and the decrease in the olefinic to lipid ratio. These effects
42
43
44 291 were seen to be more profound in inguinal adipose tissue.

45
46 292 In our immunohistological study, we aimed to differentiate brown adipose tissue and white
47
48 293 adipose tissue from each other, so transdifferentiation of these tissues could be investigated.
49
50 294 Figure 4 shows the general optical microscope images of UCP1-stained gonadal and inguinal
51
52 295 adipose tissue sections of the control and obese (BFMI861) male mice in 40X magnification.
53
54
55 296 Our studies revealed mainly three results; increased cell size, decreased UCP1 protein
56
57 297 content, and impaired membrane appearance in obese mice lines. UCP1 proteins appeared as
58
59
60 298 reddish pink color in the images. As seen from Figure 4, adipocytes in obese groups had

1
2
3 299 fewer amounts of UCP1 proteins in comparison with the control groups. When we compared
4
5 300 the amount of brown and white adipocytes in the control and obese groups, we have seen that
6
7
8 301 brown adipocytes replaced to white adipocytes significantly in all obese groups especially in
9
10 302 BFMI860 and BFMI861 mice lines and this replacement was more dramatic in inguinal
11
12 303 adipose tissue.
13
14
15 304

17 305 **4. Discussion**

19
20 306 In most healthy cases, the subcutaneous adipose tissue is especially responsible for the storage
21
22 307 of fat to supply energy fuel to all kind of cells of the organism in the periods of famine. In
23
24 308 obesity, since the storage capacity of subcutaneous adipose tissue is limited, excess lipids
25
26 309 begin to be stored in visceral adipose tissue and ectopically in other organs. These excess
27
28 310 storages certainly affect the lipid metabolism of the adipose tissues. In our study, we found
29
30 311 increased lipid amount and lipid/protein ratio, increased levels of triglycerides and cholesterol
31
32 312 esters and qualitative changes in lipid acyl chain towards longer length and decreased content
33
34 313 of unsaturation in lipid structure for obese male mice lines compared to the control group.
35
36 314 Protein metabolism was also found to be affected via decreased protein amount and changes
37
38 315 in protein structure in obese lines.
39
40
41
42

43 316 The lipid to protein ratio gives information about change in lipid content in comparison to
44
45 317 protein content. Not surprisingly, we obtained an increased lipid/protein ratio in all obese
46
47 318 groups compared to the control group. The expansion of visceral adipose tissue and
48
49 319 subcutaneous adipose tissue mass in the body is mainly reason of obesity and it generally
50
51 320 results in disturbed lipid and glucose metabolism.⁵⁵ Since the subcutaneous adipose tissue
52
53 321 storage capacity is limited due to the increase in hypertrophy progresses, excess lipids also
54
55 322 accumulate in the visceral adipose tissue stores. It has been reported that visceral adipose
56
57 323 tissue is more effective on lipid and glucose metabolism, as it is more sensitive to lipolysis
58
59
60

1
2
3 324 because of being more active, whereas subcutaneous adipose tissue is responsible for being a
4
5 325 passive storage depot.⁵⁶ In addition, excess deposition of fat in visceral adipose tissue was
6
7
8 326 reported to be more harmful than excess deposition in subcutaneous adipose tissue, because
9
10 327 lipolysis of triglycerides from visceral adipose tissue results in the release of free fatty acids
11
12 328 into the portal vein, and in turn into liver.⁵⁷

13
14
15 329 Olefinic/lipid ratio, which is an index of the content of unsaturation in lipid structure,
16
17 330 decreased in obese groups compared to the control groups.³⁸ The changes in unsaturation lipid
18
19 331 content could negatively affect structure, stability, and function of membrane.⁵⁸
20
21 332 Polyunsaturated fatty acids (PUFAs) are prone to be attacked by free radicals. These reactions
22
23 333 lead to lipid peroxidation, causing changes in unsaturated/saturated lipid composition of the
24
25 334 membranes. Several studies have suggested a role for visceral adipose tissue accumulation in
26
27 335 the pathogenesis of insulin resistance.⁵⁹ Thus, excess deposition of this type adipose tissue has
28
29 336 been associated with decreased sensitivity of glucose uptake to insulin stimulation. This
30
31 337 association can be also due to the reduced rate of free fatty acid (FFA) reesterification, and
32
33 338 increased resistance of lipolysis to the inhibitory effect of insulin in both visceral and
34
35 339 peripheral adipocytes.⁶⁰⁻⁶³

36
37
38
39
40
41 340 A higher CH₂ antisymmetric stretching/CH₃ antisymmetric stretching ratio demonstrates the
42
43 341 qualitatively longer hydrocarbon acyl chain length of lipids. All obese groups showed
44
45 342 significantly increased CH₂ to CH₃ antisymmetric stretching ratio, which implies the synthesis
46
47 343 of qualitatively longer hydrocarbon acyl chain in biological membranes.^{21,39} The changes in
48
49 344 lipid hydrocarbon chain length would produce changes in bilayer thickness, which could in
50
51 345 turn produce undesirable changes in the thermodynamic stability and passive permeability of
52
53 346 the lipid bilayer of biological membranes. Consistently, in our immunohistological staining
54
55 347 results, we obtained impaired membrane appearance in adipose tissue cells of obese groups
56
57 348 (Figure 4).
58
59
60

1
2
3 349 Carbonyl/lipid ratio indicates the levels of triglycerides and cholesterol esters in the
4
5 350 system.^{49,50,64} We obtained a significant increase in the carbonyl/lipid ratio within the adipose
6
7
8 351 tissues of the BFMI860 and BFMI861 lines, especially in inguinal adipose tissue, suggesting
9
10 352 an increased concentration of the ester groups belonging to triglycerides in adipose tissues of
11
12 353 the obese groups.^{49,65} Inguinal adipose tissue, a subcutaneous adipose tissue, demonstrated
13
14
15 354 higher carbonyl/lipid ratio than gonadal adipose tissue, a visceral adipose tissue. The results
16
17 355 are in agreement with the other studies in the literature which state that larger adipocytes
18
19 356 which consists of subcutaneous adipose tissue, synthesize more triglycerides than smaller
20
21 357 adipocytes constituting visceral adipose tissue.^{66,67} The storage of triglycerides and lipids
22
23 358 within adipose tissue in all obese lines is positively correlated with the markers of insulin
24
25 359 resistance.^{68,69} The excess release of free fatty acids arises from excess lipolysis of
26
27 360 triglycerides. The free fatty acids (FFAs) secreted at high quantities by enlarged adipocytes
28
29 361 play a critical role in the development of insulin resistance.⁷⁰ Since insulin is the main
30
31 362 regulator of hormone sensitive lipase (HSL), the rate controlling enzyme for triglyceride
32
33 363 hydrolysis, the inhibitory effect of FFAs on insulin sensitivity leads to enhanced lipolysis in
34
35 364 adipocytes.⁷¹ The adipose tissue dysfunction has a critical role in abdominal obesity in
36
37 365 vascular risk and risk of developing type 2 diabetes mellitus.⁷²
38
39 366 Adipocytes have a special ability to store large quantities of lipids that can be rapidly released
40
41 367 and used for energy by other organs when necessary; however, excessive adipose tissue,
42
43 368 especially in the visceral adipose tissue depot, is linked with increased risk of insulin
44
45 369 resistance, cardiovascular disease and cancer.^{73,74}
46
47 370 These changes in membrane lipids and lipid metabolism of adipose tissues also affect the
48
49 371 protein metabolism of tissues in obese mice lines. Decreased protein amount calculated from
50
51 372 the area value of the amide I band and the area ratios of amide I/ amide I + amide II bands in
52
53 373 obese lines imply changes in obesity-induced protein expression. In addition, the decrease in
54
55
56
57
58
59
60

1
2
3 374 amide I/amide II ratio, and the shifting of amide I wavenumber to higher values indicate
4
5 375 possible obesity-induced alterations in protein structure and conformation.⁴⁰
6
7

8 376 There are several studies reported increased and decreased expression of proteins including
9
10 377 leptin, TNF- α , IL-6 and adiponectin, IL-10, omentin, respectively in WAT adipose
11
12 378 tissues.^{70,75,76} These proteins were measured in circulation since they were given to the
13
14
15 379 circulatory system after the secretion from adipocytes.⁷⁷ However, except adiponectin which
16
17 380 is expressed only from WAT adipocytes, these proteins are also expressed from other tissues
18
19 381 and circulating cells such as hypothalamus, myocytes, hepatocytes, macrophages and
20
21
22 382 fibroblasts.^{76,77} Thus, among the proteins expressed in adipocytes, only the circulating levels
23
24 383 of adiponectin can be used to get information for the changes in protein amount in adipose
25
26 384 tissues. Together with the decrease in UCP1 protein (Figure 4), decrease in adiponectin
27
28 385 protein expression may cause a decrease in the amount of protein in adipose tissues as seen
29
30
31 386 from FTIR results (Table 2 and Figure 2).
32
33

34 387 Previous studies have shown that increased mass of adipose tissue was found to be correlated
35
36 388 with the decreased relative total protein content.⁷⁸ As a result of our immunohistological
37
38 389 staining, we obtained higher amount of white adipocytes in the obese groups than the control
39
40
41 390 group (Figure 4). This can be explained by two ways, the first one is by an increase of size
42
43 391 and number of white adipocytes. Increased white adipose tissue mass in metabolically active
44
45 392 sites activates an inflammatory process,⁶⁸ and this process creates a strong increase of
46
47 393 proinflammatory cytokines, hormone-like molecules and other inflammatory markers, defined
48
49
50 394 as “adipokines” in circulating mechanism.^{80,81} This complex physiological reaction progress
51
52
53 395 leads to an increased level of glucocorticoids, induce the development and differentiation of
54
55 396 preadipocytes, resulting in an increase of white adipose tissue mass.^{82,83} The second and more
56
57
58 397 powerful explanation can be the possibility of the transdifferentiation of brown adipocytes into
59
60 398 white adipocytes. Accordingly, in our immunohistological staining results, we observed lower

1
2
3 399 amount of UCP1 proteins in obese groups, implying a decreased amount of brown adipocytes
4
5 400 especially in subcutaneous adipose tissue. Their cohabitation could be explained by reversible
6
7
8 401 physiological transdifferentiation because they can be converted to each other, if it is
9
10 402 necessary. This capability is so crucial because, the brown adipose tissue is directly associated
11
12 403 with resistance to obesity and the brown phenotype exerts an anti-obesity effect.¹⁰
13
14
15 404 Accordingly, it has been reported that obesity-prone mice have less brown adipose tissue than
16
17 405 obesity-resistant mice.⁸⁴ It has been also suggested that visceral white adipocytes were
18
19 406 actually brown adipocytes previously, some of which turn into white adipocytes because of
20
21 407 the smaller size of visceral adipocytes and the different resistance to death of visceral and
22
23 408 subcutaneous adipocytes.¹⁰
24
25
26
27 409 Brown adipocytes have also an important role in glucose metabolism and insulin sensitivity.
28
29 410 These properties make brown adipose tissue a target for the treatment of obesity, diabetes, and
30
31 411 other metabolic disorders.⁸⁵ A recent rodent study utilizing brown adipose tissue
32
33 412 transplantation from donor mice into the visceral cavity of recipient mice, achieved to
34
35 413 increase brown adipose tissue mass, demonstrated improved glucose tolerance, increased
36
37 414 insulin sensitivity, reduced body weight, and decreased fat mass.⁸⁶ Several studies were able
38
39 415 to support brown adipose tissue transplantation experiments and obtained positive treatment
40
41 416 results.^{87,88} All these data indicate that the brown adipose tissue has very crucial role in
42
43
44 417 obesity and other metabolic diseases.
45
46
47
48
49

418

50 419 **5. Conclusion**

51
52
53 420 The results of the current study revealed an increased lipid concentration and significantly
54
55 421 decreased UCP1 protein content, implying a decrease in brown adipocytes in both adipose
56
57 422 tissues of spontaneous obese groups. These results indicated that obese (BFMI) mice lines had
58
59 423 a lower amount of brown adipocytes in visceral and subcutaneous adipose tissues, which is an
60

1
2
3 424 inclination for obesity. Moreover, the decreased unsaturation ratio, the qualitatively longer
4
5 425 hydrocarbon acyl chain length of lipids and the increased amount of triglycerides revealed by
6
7
8 426 FTIR microspectroscopy indicate that both types of adipose tissues, especially inguinal fat
9
10 427 were more prone to lipid peroxidation. It is well known that these kind of structural
11
12 428 alterations in biomolecules are strongly correlated with membrane functioning and ion
13
14
15 429 channel kinetics.^{89,90} Obesity-related structural alterations in lipids and proteins of the BFMI
16
17 430 lines, especially for BFM861 line, may be an indicator of a tendency for insulin resistance,
18
19 431 therefore type 2 diabetes, besides obesity. One important finding of the study is that both
20
21
22 432 visceral and dominantly subcutaneous adipose tissues demonstrated considerable obesity-
23
24 433 induced alterations, therefore both of them take role in the progression of obesity.
25
26
27 434 Furthermore, the current study clearly revealed the power of FTIR microspectroscopy in the
28
29 435 precise determination of spectral variations in adipose tissue components of spontaneous mice
30
31 436 models.
32

33 34 437 35 36 438 **Acknowledgement**

37
38
39 439 This work was supported by The Scientific and Technological Research Council of Turkey
40
41 440 (TUBITAK) with a grant number SBAG-110S235. This work was carried out as a part of the
42
43 441 COST Action (BM0901)-SYSGENET.
44

45 46 442 47 48 443 **References**

- 49
50 444
51 445 1. F. Zhou, J. F. Fu, C. L. Wang, L. Liang and Z.Y. Zhao, *Zhonghua Liu Xing Bing Xue Za*
52
53 446 *Zhi*, 2007, **28**, 9, 910-913.
54
55 447 2. WHO website, <http://www.who.int/mediacentre/factsheets/fs311/en>, (accessed October
56
57 448 2014).
58
59 449 3. C. M. Kastorini, H. J. Milionis, K. Esposito, D. Giugliano, J.A. Goudevenos and D.B.
60

- 1
2
3 449 Panagiotakos, *J. Am. Coll. Cardiol.*, 2011, **57**, 1299–1313.
4
5
6 450 4. G. I. Schulman, *J. Clin. Invest.*, 2000, **106**, 171-176.
7
8 451 5. R. H. Unger and L. Orci, *FASEB J.*, 2001, **15**, 312-321.
9
10 452 6. J. E. Schaffer, *Curr. Opin. Lipidol.*, 2003, **14**, 3, 281-287.
11
12 453 7. S. Cinti, *Prostaglandins Leukot. Essent. Fatty Acid*, 2005, **73**, 9-15.
13
14
15
16 454 8. E. E. Kershaw and J. S. Flier, *J. Clin. Endocrinol. Metab.*, 2004, **89**, 2548-2556.
17
18 455 9. C.H. Saely, K. Geiger and H. Drexel, *Gerontology*, 2010, **58**, 1, 15-23.
19
20 456 10. S. Cinti, *Am. J. Physiol Endocrinol. Metab.*, 2009, **297**, 977–986.
21
22 457 11. B. Cannon and L. Nedergaard, *Physiol. Rev.*, 2004, **84**, 277-359.
23
24 458 12. S. Klaus, L. Casteilla, F. Bouillaud and D. Ricquier, *Int. J. Biochem.*, 1991, **23**, 791-801.
25
26 459 13. B. Cannon, A. Hedin and J. Nedergaard, *FEBS Lett.*, 1982, **150**, 129-132.
27
28 460 14. S. Cinti, *Nutr. Metab. Cardiovasc. Dis.*, 2006, **16**, 569-574.
29
30 461 15. S. Cinti, *Int. J. Pediatr. Obes. Suppl.*, 2008, **2**, 21-26.
31
32 462 16. R. Canello, M. C. Zingaretti, R. Sarzani, D. Ricquier and S. Cinti, *Endocrinology*, 1998,
33
34 **139**, 4747-4750.
35
36 464 17. J. W. Bortolotto, C. Reis, A. Ferreira, S. Costa, C. C. Mottin, A. A. Souto and R. M.
37
38 Guaragna, *Obesity Surgery*, 2005, **15**, 1265-1270.
39
40 466 18. A. Dogan, P Lasch, C. Neuschl, M.K. Millrose, R. Alberts, K. Schughart, D. Naumann
41
42 and G.A. Brockmann, *BMC Genomics*, 2013, **14**, 386.
43
44 467 19. D. S. Lester, L. H. Kidder, I. W. Levin and E. N. Lewis, *Cell Mol. Biol.*, 1998, **44**, 29-38.
45
46 468 20. K. Z. Liu, A. Man, R. A. Shaw, B. Liang, Z. Xu and Y. Gong, *Biochim. Biophys. Acta.*,
47
48 2006, **1758**, 960-967.
49
50 469 21. G. Cakmak, L.M. Miller, F. Zorlu and F. Severcan, *Arch. Biochem. Biophys.*, 2012, **520**,
51
52 67-73.
53
54 470
55
56 471 22. O. Bozkurt, S. Haman Bayari, M. Severcan, C. Krafft, J. Popp and F. Severcan, *J.*
57
58
59
60

- 1
2
3 474 *Biomed. Opt.*, 2012, **17**, 7, 076023.
- 4
5 475 **23.** J. Kneipp, M. Beekes, P. Lasch and D. Naumann, *J. Neurosci*, 2002, **22**, 8, 2989-2997.
- 6
7 476 **24.** A. Marcelli, A. Cricenti, A. Kwiatek and C. Petibois. *Biotechnol. Adv.*, 2012, **30**, 6, 1390-
8 477 1404.
- 9
10 478 **25.** A. Wagener, A. O. Schmitt, S. Aksu, W. Schlote, C. Neuschl and G. A. Brockmann,
11 479 *Physiol. Genomics*, 2006, **27**, 264-270.
- 12
13 480 **26.** A. Hantschel, A. Wagener, C. Neuschl, D. Teupser and G. A. Brockmann, *Obesity Facts*,
14 481 2011, **4**, 270-277.
- 15
16 482 **27.** R. S. Hageman, A. Wagener, C. Hantschel, K. L. Svenson, G. A. Churchill and G.A.
17 483 Brockmann, *Physiol. Genomics*, 2010, **42**, 55-66.
- 18
19 484 **28.** K. L. Svenson, R. von Smith, P. A. Magnani, H. R. Suetin, B. Paigen, J. K. Naggert, R.
20 485 Li, G. A. Churchill and L. L. Peters, *J. Appl. Physiol.*, 2007, **102**, 2369-2378.
- 21
22 486 **29.** X. Bi, G. Li, S. B. Doty and N. P. Camacho, *Osteoarthritis Cartilage*. 2005, **13**, 12,
23 487 1050-1058.
- 24
25 488 **30.** P. A. West, M. P. G. Bostrom, P. A. Torzilli and N. P. Camacho, *Applied Spectroscopy*,
26 489 2004, **58**, 4, 376-381.
- 27
28 490 **31.** A. L. Boskey, M. Goldberg, A. Kulkarni and S. Gomez, *Biochimica et Biophysica Acta*,
29 491 2006, **1758**, 942-947.
- 30
31 492 **32.** A. Dogan, K. Ergen, F. Budak and F. Severcan, *Appl. Spectrosc.*, 2007, **61**, 2, 199-203.
- 32
33 493 **33.** I. W. Levin and R. Bhargava, *Annu. Rev. Phys. Chem.*, 2005, **56**, 429-474.
- 34
35 494 **34.** R. Gasper, J. Dewelle, R. Kiss, T. Mijatovic and E. Goormaghtigh, *Biochim. Biophys*
36 495 *.Acta.*, 2009, **1788**, 1263-1270.
- 37
38 496 **35.** D. Naumann, in *Infrared and Raman Spectroscopy of Biological Materials*, ed. H. U.
39 497 Gremlich and B. Yan, Marcel Dekker, New York, vol. 24, ch. 9, pp. 323-379.
- 40
41 498 **36.** D. Naumann, H. Fabian and P. Lasch, in *Biological and Biomedical Infrared*

- 1
2
3 499 *Spectroscopy*, ed. A. Barth and P.I. Haris, IOS Press, Netherlands, ch. 12, pp 312-357,
4
5 500 2009.
6
7
8 501 **37.** N. S. Ozek, S. Tuna, A. E. Erson-Bensan and F. Severcan, *Analyst*, 2010, **135**, 12, 3094-
9
10 502 3102.
11
12 503 **38.** J. Kneipp, P. Lasch, E. Baldauf, M. Beekes and D. Naumann, *Biochim. Biophys. Acta.*,
13
14 504 2000, **1501**, 189-199.
15
16
17 505 **39.** Q. Wang, W. Sanad, L.M. Miller, A. Voigt, K. Klingel, R. Kandolf, K. Stangl and G.
18
19 506 Baumann, *Vib. Spectrosc.*, 2005, **38**, 217-222.
20
21
22 507 **40.** O. Bozkurt, M. Severcan and F. Severcan, *Analyst*, 2010, **135**, 3110-3119.
23
24 508 **41.** K.P. Ishida and P.R. Griffiths, *Appl. Spectrosc.*, 1993, **47**, 584-589.
25
26
27 509 **42.** M. M. Ibrahim, *Obes. Rev.*, 2010, **11**, 1, 11-18.
28
29 510 **43.** G. Cakmak, F. Zorlu, M. Severcan and F. Severcan, *Anal. Chem*, 2011, **83**, 7, 2438-2444.
30
31 511 **44.** P. Yu, D. Kevin and L. J. Dasen, *Agric. Food Chem.*, 2008, **56**, 3417-3426.
32
33
34 512 **45.** M. Schmidt, T. Wolfram, M. Rumpler, C. P. Tripp and M. Grunze, *Biointerphases*, 2007,
35
36 513 **2**, 1-5.
37
38 514 **46.** Y. Adigüzel, P. I. Haris and F. Severcan, in *Vibrational Spectroscopy in Diagnosis and*
39
40 515 *Screening*, ed. F. Severcan and P. I. Haris, IOS Press, Netherlands ,2012, ch. 3, pp.72-78
41
42
43 516 **47.** G. Cakmak, I. Togan and F. Severcan, *Aquat Toxicol.*, 2006, **77**, 1, 53-63.
44
45 517 **48.** P.I. Haris and F. Severcan, *J. Mol. Catal. B: Enzym*, 1999, **7**, 207-221.
46
47
48 518 **49.** M. Nara, M. Okazaki and H. Kagi, *Chem. Phys. Lipids*, 2002, **117**, 1-6.
49
50 519 **50.** G. Voortman, J. Gerrits, M. Altavilla, M. Henning, L. van Bergeijk and J. Hessels, *Clin.*
51
52 520 *Chem. Lab. Med.*, 2002, **40**, 795-798.
53
54
55 521 **51.** S. Kumar, T. S. Shabi and E. Goormaghtigh, PLoS ONE, 2014, **9**, 11, DOI:
56 522 10.1371/journal.pone.0111137.
57
58 523 **52.** A. Derenne, O. Vandersleyen and E. Goormaghtigh, *Biochim Biophys Acta.*, 2014, **1841**,
59
60 524 8, 1200-1209.

- 1
2
3 525 **53.** B. L. Smiley and G. L. Richmond., *J. Phys. Chem. B*, 1999, **103**, 4, 653–659.
- 4
5 526 **54.** K. M. Antoine, S. Mortazavi, A. D. Miller and L. M. Miller, *J Forensic Sci.*, 2010, **55**, 2,
6
7 527 513-518.
- 8
9 528 **55.** H. E. Bays, J. M. Gonzalez-Campoy, G. A. Bray, A. E. Kitabchi, D.A. Bergman, A. B.
10
11 Schorr, H. W. Rodbard and R. R. Henry, *Expert. Rev. Cardiovasc. Ther.*, 2008, **6**, 3, 343-
12
13 529 368.
- 14
15 530
16
17 531 **56.** E. Bonora, S. Del Prato, R. C. Bonadonna, G. Gulli, A. Solini and M. L. Shank, *Diabetes*,
18
19 532 1992, **41**, 9, 1151-1159.
- 20
21 533 **57.** P. Bjorntorp, *Arteriosclerosis*, 1990, **10**, 493-496.
- 22
23 534 **58.** R. N. A. H. Lewis and R. N. McElhaney, in *The Structure of Biological Membranes*, ed.
24
25 P. L. Yeagle, CRC Press, New YORK, 3rd edn, 2011, ch. 4 , pp 29-36.
- 26
27 535
28
29 536 **59.** Y. Gastaldelli, M. Miyazaki, M. Pettiti, S. Matsuda, E. Mahankali, R.A. Santini DeFronzo
30
31 537 and E.J. Ferrannini, *Clin. Endocrinol. Metab.*, 2002, **87**, 11, 5098-5103.
- 32
33 538 **60.** M. Broche, R. D. Starling, A. Tchernof, D. E. Matthews, E. Garcia-Rubi and E. T.
34
35 Poehlman, *J. Clin. Endocrinol. Metab.*, 2000, **85**, 2378–2384.
- 36
37 539
38
39 540 **61.** J. R. Zierath, J. N. Livingston, A. Thorne, J. Bolinder, S. Reynisdottir, F. Lonnqvist and P.
40
41 541 Arner, *Diabetologia*, 1998, **41**, 1343–1354.
- 42
43 542 **62.** S. E. Meek, K. S. Nair and M. D. Jensen, *Diabetes*, 1999, **48**, 10–14.
- 44
45 543 **63.** J. B. Albu, M. Curi, M. Shur, L. Murphy, D.E. Matthews and F. X. Pi-Sunyer, *Am. J.*
46
47 544 *Physiol.*, 1999, **277**, 551-560.
- 48
49 545 **64.** N. S. Ozek, Y. Sara, R. Onur and F. Severcan, *Biosci. Rep.*, 2010, **30**, 41-50.
- 50
51 546 **65.** G. Cakmak, I. Togan, C. Uguz and F. Severcan, *Appl. Spectrosc.*, 2003, **57**, 835-841.
- 52
53 547 **66.** N. K. Edens, S. K. Fried, J. G. Kral, J. Hirsch and R. L. Leibel, *Am. J. Physiol.*, 1993, **265**,
54
55 548 374-379.
- 56
57 549 **67.** C. Farnier, S. Krief, M. Blache, F. Diot-Dupuy, G. Mory, P. Ferre and R. Bazin, *Int. J.*

- 1
2
3 550 *Obes. Relat. Metab. Disord.*, 2003, **27**, 1178- 1186.
- 4
5 551 **68.** D. A. Pan, S. Lillioja, A. D. Kriketos, M. R. Milner, L. A. Baur, C. Bogardus, A. B.
6
7
8 552 Jenkins and L. H. Storlien, *Diabetes*, 1997, **46**, 983-988.
- 9
10 553 **69.** D. I. Phillips, S. Caddy, V. Ilic, B. A Fielding, K. N Frayn, A. C Borthwick and R. Taylor,
11
12
13 554 *Metabolism*, 1996, **45**, 947-950.
- 14
15 555 **70.** G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson and B. M. Spiegelman, *J. Clin.*
16
17 556 *Invest.*, 1995, **95**, 2409–2415.
- 18
19 557 **71.** H. Ruan, N. Hacoheh, T. R. Golub, L. van Parijs and H. F. Lodish, *Diabetes*, 2002, **51**,
20
21 558 1319–1336.
- 22
23 559 **72.** G. R. Hajer, T.W. van Haeften and F. L. J. Visseren, *European Heart Journal*, 2008, **29**,
24
25 560 2959–2971.
- 26
27 561 **73.** P. Hossain, B. Kavar and M. El Nahas, *N. Engl. J. Med.*, 2007, **356**, 213–215.
- 28
29 562 **74.** D.H. Cohen and D. Leroith, *Endocr. Relat. Cancer*, 2012, **19**, 27–45.
- 30
31 563 **75.** M. Qatanani and M. A. Lazar, *Genes Dev.*, 2007, **21**, 12, 1443-1455.
- 32
33 564 **76.** K. Makki, P. Froguel and I. Wolowczuk, *ISRN Inflamm.*, 2013,
34
35 565 DOI:10.1155/2013/139239.
- 36
37 566 **77.** M. K. Piya, P. G. McTernan and S. Kumar, *J Endocrinol.* 2013, **216**, 1, T1-T15.
- 38
39 567 **78.** P. M. Seraphim, M. T. Nunes and U. F. Machado, *Braz. J. Med. Biol. Res.*, 2001, **34**, 10,
40
41 568 1353-1362.
- 42
43 569 **79.** R. Canello and K. Clément, *International Journal of Obstetrics & Gynaecology*, 2006,
44
45 570 **113**, 10, 1141–1147.
- 46
47 571 **80.** F. Lago, C. Dieguez, J. Gómez-Reino and O. Gualillo, *Nature Clinical Practice*
48
49 572 *Rheumatology*, 2007, **3**, 12, 716–724.
- 50
51 573 **81.** S. E. Wozniak, L. L. Gee, M. S. Wachtel and E. E. Frezza, *Digestive Diseases and*
52
53 574 *Sciences*, 2009, **54**, 9, 1847–1856.

- 1
2
3 575 **82.** J. Q. Purnell, S. E. Kahn, M. H. Samuels, D. Brandon, D. L. Loriaux and J. D. Brunzell,
4
5 576 *American Journal of Physiology*, 2009, **296**, 2, 351–357.
6
7
8 577 **83.** V. Bourlier, A. Zakaroff-Girard and A. Miranville, *Circulation*, 2008, **117**, 6, 806–815.
9
10 578 **84.** K. Almind, M. Manieri, W. I. Sivitz, S. Cinti and C. R. Kahn, *Proc. Natl. Acad. Sci.*,
11
12 579 2007, **104**, 2366–2371.
13
14 580 **85.** K. L. Townsend and Y. H. Tseng, *Adipocyte*, 2012, **1**, 13–24.
15
16 581 **86.** K. I. Stanford, R. J. W. Middelbeek, K. L. Townsend, D. An, E. B. Nygaard, K. M.
17
18 582 Hitchcox, K. R. Markan, K. Nakano, M. F. Hirshman, Y. Tseng and L. J. Goodyear, *J.*
19
20 583 *Clin. Invest.*, 2013, **123**, 215–223.
21
22 584 **87.** S. C. Gunawardana and D. W. Piston, *Diabetes*, 2012, **61**, 674–682.
23
24 585 **88.** X. Liu, Z. Zheng, X. Zhu, M. Meng, L. Li, Y. Shen, Q. Chi, D. Wang, Z. Zhang, C. Li, Y.
25
26 586 Li, Y. Xue, J.R. Speakman and W. Jin, *Cell Res.*, 2013, **23**, 851–854.
27
28 587 **89.** A. A. Spector and M. A. Yorek, *J. Lipid Res.*, 1985, **26**, 9, 1015-1035.
29
30 588 **90.** M. S. Awayda, W. Shao, F. Guo, M. Zeidel and W. G. Hill, *J. Gen. Physiol.*, 2004, **1238**,
31
32 589 6, 709-727.
33
34 590
35
36 591
37
38 592
39
40 593
41
42 594
43
44 595
45
46 596
47
48 597
49
50 598
51
52 599
53
54 600
55
56
57
58
59
60

601 **Table 1.** General band assignment of FTIR spectrum of an adipose tissue.^{18,35,36}

Band No	Wavenumber (cm-1)	Definition of the spectral assignment
1	3290	N–H and O–H stretching: Mainly N–H stretching (amide A) of proteins with the little contribution from O–H stretching of polysaccharides, carbohydrates and water
2	3005	Olefinic=CH stretching vibration: unsaturated lipids, cholesterol esters
3	2957	CH ₃ anti-symmetric stretching: lipids, protein side chains, with some contribution from carbohydrates and nucleic acids
4	2924	CH ₂ anti-symmetric stretching: mainly lipids, with some contribution from proteins, carbohydrates, nucleic acids
5	2875	CH ₃ symmetric stretching: mainly protein side chains, with some contribution from lipids, carbohydrates and nucleic acids
6	2855	CH ₂ symmetric stretching: mainly lipids, with some contribution from proteins, carbohydrates, nucleic acids
7	1744	Carbonyl C=O stretch: triglycerides
8	1654	Amide I (protein C=O stretching)
9	1545	Amide II (protein N-H bend, C-N stretch)

602

603

604

605

606

607

608

609

610

611

612

613

Table 2. The band area and band position values of the amide I band in male control (DBA/2J) and obese (BFMI lines) mice gonadal and inguinal adipose tissues.

		Control	BFMI852	BFMI856	BFMI860	BFMI861
Amide I area value	Gonadal	0.83±0.01	0.63±0.04*	0.42±0.03*	0.38±0.02**	0.37±0.03**
	Inguinal	0.73±0.04	0.57±0.05	0.56±0.02	0.33±0.04**	0.29±0.01**
Amide I band position	Gonadal	1652.56±0.30	1653.50±0.13*	1654.53±0.51*	1655.31±0.25**	1656.65±0.60**
	Inguinal	1652.93±0.93	1653.31±0.42*	1654.57±0.18**	1656.85±0.29**	1656.94±0.28**

The values are the mean ± standard error of the mean for each group. Comparison was performed by one-way ANOVA and Tukey's test was used as a post test. The degree of significance was denoted with * for the comparison of control DBA/J2 strain with other BFMI lines. P values less than or equal to 0.05 were considered as statistically significant; * $p \leq 0,05$; ** $p \leq 0,01$; *** $p \leq 0,001$.

Table 1S. The spectral regions and baseline points for particular infrared bands used in calculation of band area ratios.

Infrared band	Integrated spectral region (cm ⁻¹)	Baseline points (cm ⁻¹)
Olefinic=CH	3020-2992	3100-2740
CH ₃ antisymmetric stretching	2976-2948	3100-2740
CH ₂ antisymmetric stretching	2940-2916	3100-2740
CH ₃ symmetric stretching	2880-2864	3100-2740
CH ₂ symmetric stretching	2864-2844	3100-2740
C-H region	2980-2830	3100-2740
Carbonyl (C = O) stretching	1764-1724	1850-1500
Amide I	1672-1636	1850-1500
Amide II	1560-1536	1850-1500

631

Legends of Figures

633

Figure 1. Representative FTIR spectra of IF adipose tissue of male control DBA/J2 and obese BFMI861 line in the 4000-750 cm^{-1} region.

Figure 2. The bar graphs of the lipid/protein, CH_2 symmetric/ CH_2 antisymmetric, CH_2/CH_3 antisymmetric, olefinic/lipid, carbonyl/lipid, CH_2 antisymmetric/lipid, amide I/ amide II, amide I/ amide I + amide II ratios of control (DBA/J2) and 4 different obese (BFMI) male mice lines (n=6 for each line). The degree of significance was denoted by * for the comparison of control DBA/J2 line with BFMI lines as: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ and by + for the comparison of gonadal adipose tissue with inguinal adipose tissue in same line as: $+p < 0.05$, $++p < 0.01$, $+++p < 0.001$.

Figure 3. The representative spectral maps of lipid/protein, olefinic/protein and CH_2/CH_3 antisymmetric ratios belong to inguinal adipose tissue of control (DBA/J2) and obese (BFMI861) male mice line. The absorbance in the spectral maps was represented in color-coded images, where low absorption was represented in blue and high absorption was represented in red color.

Figure 4. Immunohistological UCP1 staining results of gonadal and inguinal adipose tissues which belong to the control and obese (BFMI861) male mice. Microscopic images of Gonadal adipose tissue of control group (A), inguinal adipose tissue of the control group (B), gonadal adipose tissue of the obese group (C), inguinal adipose tissue of the obese group (D) in 40X magnification. The regions which are shown by arrows are brown adipose tissue and the rest of the cells belong to white adipose tissue.

654

655





Figure 1

675

676



677

678

Figure 2

679

680

681

682

683

684

685

686

687

688





Figure 3

689
690
691
692
693
694
695
696
697
698
699
700
701
702
703

704



705

706

Figure 4

707

708

709

710

711

712

713

714

715

716

717

718

719


720

721

722

723

1
2
3 724
4
5
6
7
8
9
10
11
12
13
14 725
15
16 726
17
18 727
19
20 728
21
22 729
23
24 730
25
26 731
27
28 732
29
30 733
31
32 734
33
34 735
35
36 736
37
38 737
39
40 738
41
42 739
43
44 740
45
46 741
47
48 742
49
50 743
51
52 744
53
54 745
55
56
57
58
59
60



Graphical Abstract

1
2
3 746 **Textual abstract**
4

5 747 FTIR microspectroscopy coupled with UCP1 immunohistological staining enable to detect
6

7
8 748 obesity-related molecular alterations and transdifferentiation in visceral and subcutaneous
9

10 749 adipose tissues in spontaneous obese mice lines.
11

12
13 750

14
15 751

16
17 752
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60